ARCHIVES

Leter: Payers Must Determine Appropriate Therapies

This article is from The Cancer Letter archive.

Vol. 22 No. 29 | July 19, 1996

Download PDF Visit The Full Archive

Related Articles

DCT Board Approves Phase 2/3 Studies Of LAK-IL-2

February 14, 1986

DCT Board Approves Concepts For Three Radiation Research RFAs

March 6, 1987

In Brief: Data Availability From Cancer Survey Presents Problems – Who Gets It first, Confidentiality

August 30, 1974

Mouse Strains Now Available From NCI

March 18, 1983

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

April 5, 1985

House Committee Seeks Information on ImClone Insider Stock Trading.

March 29, 2002